Staff
Janice Reichert, PhD, Executive Director
Dr. Janice Reichert, Executive Director of The Antibody Society, is an internationally-recognized expert in the development of antibody therapeutics. She is Founder and Managing Director of Reichert Biotechnology Consulting LLC, a biopharmaceutical business intelligence research firm, and Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.
Relevant links:
Editor-in-chief, mAbs
Kaplon & Reichert, Antibodies to watch in 2021. mAbs 2021
Neeti Sinha, Education & Outreach Program Manager
Dr. Neeti Sinha has an academic background in diverse scientific fields that include computational molecular biophysics, theoretical thermodynamics, leading physics, and for all purposes of beauty in intricacy and complexity, mathematics. She has many years of research, teaching, and outreaching, experience in leading scientific fields. She holds a DPhil degree in biochemistry from Oxford University, UK. She was a postdoctoral scholar at the National Institutes of Health, following which she worked as an assistant research professor at the Johns Hopkins University. Her work at NIH & Johns Hopkins University involved understanding fundamentals of protein structure-function relations & thermodynamic approaches to computational drug design. Neeti frequently speaks at scientific meetings on topics that inspire the elegance in physics and mathematics, and advanced sciences in general. Find out more about her at her blog: Cosmic Landscape in Quantum Décor. She welcomes a LinkedIn connection. Neeti joined the Antibody Society in March of 2021 as Program Manager, Education & Outreach. Her earlier work on the physical principles of antibody-antigen interactions and her current interest of education and outreach in advanced scientific fields came together to motivate her toward joining the mission of The Antibody Society.
Simon Goodman, Science & Technology Program Manager
Dr. Simon L. Goodman has spent most of his career working on molecules regulating cell adhesion. Simon was with Merck KGaA in Darmstadt, Germany from 1993 to 2013, most recently leading the immunohistology group in the Translational and Biomarkers research section of oncology preclinical pharmaceutical research, developing and validating antibodies for clinical biomarker analysis. Prior to that, as principal scientist, he was preclinical leader on the cilengitide drug development team, where he supported the anti-adhesion drug through Phase 1, 2 and 3 trials, including presenting the drug to the NCI as an IND. This followed 15 years as head of a cell biology laboratory in Merck, where he was involved in drug discovery. Before Merck, he studied cell adhesion processes at various Max-Planck institutes. He has published over 100 highly cited research papers. In the UK Dr. Goodman worked at the Imperial Cancer Research Fund developing the colloidal gold system for immuno-scanning electron microscopy, and on cytokeratins. He graduated from the University of Sussex where he also gained his DPhil., in membrane biochemistry, in 1977. He is a Londoner.
Volunteers
Communications & Membership Committee
Raquel Barroso Ferro, University of Aberdeen.
Raquel Barroso Ferro, student volunteer for the Education and Career Sub-Committee, is a first year PhD student at the University of Aberdeen, UK, currently working to develop a novel scFv-based immunotherapy against ovarian cancer. She previously completed an integrated Master’s in Biochemistry (MSci) from King’s College London and worked as a research assistant evaluating how various environmental chemicals can influence aspects of the human physiology. @ LinkedIn
Silvia Crescioli, PhD, King’s College London
Dr. Silvia Crescioli is a senior post doc at King’s College London in Prof. Sophia Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she leads and supervises several projects focused on different areas of cancer immunology and immunotherapy, such as the study of B cells in cancer, antigen/antibody discovery, ADC development, and antibody production, engineering and glycoengineering. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence. @ King’s College London;
Scientific publications
Nick Hutchinson, PhD, FUJIFILM
Dr. Nick Hutchinson is the Business Steering Group Lead for Mammalian Cell Culture processes at FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing service provider for biopharmaceutical clients. He is part of the Enterprise Business Planning team and focuses on long-term projects, including capital investments and innovation. His expertise is in the biomanufacturing of biopharmaceuticals, in particular antibody therapeutics from cell line development activities through to commercial production. Dr. Hutchinson is currently an Assistant Editor for mAbs and received his Doctorate in Biochemical Engineering from University College London.
Recent presentations and publications:
Hutchinson N. 2020. Antibody Manufacturing Strategies to Address a Pandemic. Festival of Biologics. November 02-06, 2020
Reichert JM & Hutchinson N. 2020. Antibodies to Watch in 2021: Anti-SARS-CoV-2 target therapies to the rescue. The Antibody Society Webinar Series “Antibodies to Watch”. December 3, 2020. Watch it online
Hutchinson N. 2020. Tracking Therapeutic Antibody Development in a Pandemic. BioProcess International. October 2020.
Victor Greiff, PhD, University of Oslo
Dr. Victor Greiff is an Associate Professor for Systems Immunology at the University of Oslo. His group develops machine learning, computational and experimental tools for analyzing antibody and T-cell repertoires to develop immune-repertoire-based immunodiagnostics and immunotherapeutics. Dr. Greiff received his PhD in Systems Immunology from Humboldt University (Germany) and did his postdoctoral training at ETH Zürich (Switzerland). @ His website; Twitter; LinkedIn
Recent publications:
Akbar et al. A compact vocabulary of paratope-epitope interactions enables predictability of antibody-antigen binding. Cell Reports 2021.
Greiff et al. Mining adaptive immune receptor repertoires for biological and clinical information using machine learning. Current Opinion in Systems Biology
Alicia Chenowith, PhD, King’s College London
Dr. Alicia Chenoweth is a postdoctoral research associate in the Cancer Antibody Discovery and Immunotherapy group led by Prof. Sophia Karagiannis at King’s College London. Her work is focused on Fc engineering of antibodies for breast cancer therapy to better engage and influence the immune microenvironment. She received her PhD in Melbourne, Australia, under the supervision of Prof. Mark Hogarth, focusing on the interactions of human and non-human primate IgG antibodies with Fc receptors, and the impact of IgG Fc modification on immune cell function. Dr. Chenoweth is currently the co-chair of the Gordon Research Seminar for Antibody Biology and Engineering, to be held in 2022. @ LinkedIn; Twitter
Vaishali Kapoor, PhD, Washington University in St. Louis
Dr. Vaishali Kapoor is an Assistant Professor in the Department of Radiation Oncology at the Washington University in St. Louis School of Medicine. Dr. Kapoor received her PhD in Cancer Biology from the All India Institute of Medical Sciences (New Delhi, India) and did her postdoctoral training at the Washington University School of Medicine. Her research involves development of novel drug candidates against radiation-inducible neo-antigens. Her lab is developing ways to target radiation sensitizers specifically to cancer with the goal of enhancing the efficacy of radiation therapy. Dr. Kapoor is also interested in understanding the mechanisms of resistance to standard-of-care cancer therapies. @ LinkedIn; Twitter; Washington University
